Re-framing ‘counterfeit from a public health perspective’: A case for fraudulent medicine

‘Black market’ counterfeiters operating outside of authorised industry are often framed as the perpetrators of dangerous and defective medicines within legal pharmaceutical markets. However, the assumption that all medicines which deliberately violate regulatory standards and quality specifications...

Full description

Saved in:  
Bibliographic Details
Main Author: Bandiera, Rhiannon (Author)
Contributors: Marmo, Marinella
Format: Electronic Article
Language:English
Published: 2017
In: The Australian and New Zealand journal of criminology
Online Access: Volltext (Resolving-System)
Journals Online & Print:
Drawer...
Check availability: HBZ Gateway
Keywords:

MARC

LEADER 00000naa a22000002 4500
001 1736848011
003 DE-627
005 20201028091917.0
007 cr uuu---uuuuu
008 201028s2017 xx |||||o 00| ||eng c
024 7 |a 10.1177/0004865815626768  |2 doi 
035 |a (DE-627)1736848011 
035 |a (DE-599)KXP1736848011 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
100 1 |a Bandiera, Rhiannon  |e VerfasserIn  |4 aut 
245 1 0 |a Re-framing ‘counterfeit from a public health perspective’  |b A case for fraudulent medicine 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a ‘Black market’ counterfeiters operating outside of authorised industry are often framed as the perpetrators of dangerous and defective medicines within legal pharmaceutical markets. However, the assumption that all medicines which deliberately violate regulatory standards and quality specifications have black market origins is ill conceived, as poor medicine quality can occur regardless of who the manufacturer of the medicine may be. This paper proposes a reframing of all pharmaceutical products which intentionally, or negligently, fail to comply with regulatory standards and which are then fraudulently depicted as being of standard, from ‘counterfeit’ to ‘fraudulent medicines’. This proposal is reinforced with examples from Australian law, where Australian pharmaceutical companies, who deliberately violated regulatory standards and produced defective and dangerous medicines, have been prosecuted using legislation designed to capture poor-quality counterfeit drugs. The paper argues that these corporate crimes should not be framed as ‘counterfeiting’ but as ‘frauds’, thus containing acts of ‘counterfeiting’ to existing intellectual property law and providing due recognition for all acts which defraud and cause harm to the consumer. 
700 1 |a Marmo, Marinella  |d 1973-  |e VerfasserIn  |0 (DE-588)1052242448  |0 (DE-627)788070916  |0 (DE-576)285100173  |4 aut 
773 0 8 |i Enthalten in  |t The Australian and New Zealand journal of criminology  |d London ˜[u.a.]œ : Sage Publ., 1968  |g 50(2017), 2, Seite 195-212  |h Online-Ressource  |w (DE-627)355118904  |w (DE-600)2089449-1  |w (DE-576)102554234  |x 1837-9273  |7 nnns 
773 1 8 |g volume:50  |g year:2017  |g number:2  |g pages:195-212 
856 4 0 |u http://dx.doi.org/10.1177/0004865815626768  |x Resolving-System  |3 Volltext 
936 u w |d 50  |j 2017  |e 2  |h 195-212 
951 |a AR 
ELC |a 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 3788147431 
LOK |0 003 DE-627 
LOK |0 004 1736848011 
LOK |0 005 20201028091917 
LOK |0 008 201028||||||||||||||||ger||||||| 
LOK |0 040   |a DE-21-110  |c DE-627  |d DE-21-110 
LOK |0 092   |o n 
LOK |0 689   |a s  |a Counterfeit medicine 
LOK |0 689   |a s  |a Fraudulent medicine 
LOK |0 689   |a s  |a Intellectual property 
LOK |0 689   |a s  |a Intellectual property maximalism 
LOK |0 689   |a s  |a Medicine fraud 
LOK |0 689   |a s  |a Public interest 
LOK |0 852   |a DE-21-110 
LOK |0 852 1  |9 00 
LOK |0 935   |a krub  |a krzo 
ORI |a SA-MARC-krimdoka001.raw